Austin Dulak

8.2k total citations
16 papers, 675 citations indexed

About

Austin Dulak is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Austin Dulak has authored 16 papers receiving a total of 675 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Austin Dulak's work include Protein Degradation and Inhibitors (4 papers), CAR-T cell therapy research (2 papers) and Liver physiology and pathology (2 papers). Austin Dulak is often cited by papers focused on Protein Degradation and Inhibitors (4 papers), CAR-T cell therapy research (2 papers) and Liver physiology and pathology (2 papers). Austin Dulak collaborates with scholars based in United States, United Kingdom and France. Austin Dulak's co-authors include Zhenghe Wang, Fangdong Zou, John S. Lazo, Jian Yu, Peng Wang, Lin Zhang, Hua Li, Robert J. Tomko, Xiaodong Zhang and Jill M. Siegfried and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

In The Last Decade

Austin Dulak

16 papers receiving 669 citations

Peers

Austin Dulak

ONCOL

PRM

HEPAT

Dan Lu China

Jincai Wu China

Yingqiu Y. Liu United States

Josef Straub Germany

Christine To Canada

Paul Perrotte Canada

Kazuma Sakuraba Japan

Xiaokai Yan China

Tianhong Su China

Dan Lu China

Austin Dulak

458 ×1.0

131 ×0.5

203 ×1.3

ONCOL

85 ×0.8

PRM

70 ×1.0

HEPAT

Citations per year, relative to Austin Dulak Austin Dulak (= 1×) peers Dan Lu

Countries citing papers authored by Austin Dulak

Since Specialization

Citations

This map shows the geographic impact of Austin Dulak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Austin Dulak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Austin Dulak more than expected).

Fields of papers citing papers by Austin Dulak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Austin Dulak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Austin Dulak. The network helps show where Austin Dulak may publish in the future.

Co-authorship network of co-authors of Austin Dulak

This figure shows the co-authorship network connecting the top 25 collaborators of Austin Dulak. A scholar is included among the top collaborators of Austin Dulak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Austin Dulak. Austin Dulak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Ren, Xiaoxin, Austin Dulak, Matthew Rausch, et al.. (2022). 489 NPX267, a first-in-class monoclonal antibody targeting KIR3DL3, blocks HHLA2-mediated immunosuppression and potentiates T and NK cell-mediated antitumor immunity. Regular and Young Investigator Award Abstracts. A510–A510. 5 indexed citations

Moodley, Devapregasan, Austin Dulak, Ricard Masia, et al.. (2021). Abstract 1802: CD39 inhibition shapes the transcriptional landscape of myeloid cells and induces proinflammatory states in the CT26 syngeneic tumor model. Cancer Research. 81(13_Supplement). 1802–1802. 2 indexed citations

Dulak, Austin, Marc O. Johnson, Secil Koseoglu, et al.. (2020). Abstract 6639: SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies. Cancer Research. 80(16_Supplement). 6639–6639. 7 indexed citations

Lake, Andrew C., C A Wells, Ernest Smith, et al.. (2020). 726 SRF114 is a fully human, CCR8 selective IgG1 antibody that induces destruction of tumor Tregs through ADCC. SHILAP Revista de lepidopterología. A434.2–A435. 3 indexed citations

Zhang, Jingwen, Austin Dulak, Maureen M. Hattersley, et al.. (2018). BRD4 facilitates replication stress-induced DNA damage response. Oncogene. 37(28). 3763–3777. 67 indexed citations

Rhyasen, Garrett W., Yi Yao, Jingwen Zhang, et al.. (2018). BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS ONE. 13(7). e0200826–e0200826. 41 indexed citations

Yeh, Tammie C., Greg O’Connor, Philip Petteruti, et al.. (2017). Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors. Clinical Cancer Research. 23(4). 1025–1035. 16 indexed citations

Greenawalt, Danielle, Winnie S. Liang, Sakina Saif, et al.. (2017). Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum. Oncotarget. 8(59). 99237–99244. 17 indexed citations

Wappett, Mark, et al.. (2016). Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs. BMC Genomics. 17(1). 65–65. 15 indexed citations

10.

Rhyasen, Garrett W., Yi Yao, Austin Dulak, et al.. (2016). Abstract 1971: BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer. Cancer Research. 76(14_Supplement). 1971–1971. 1 indexed citations

11.

Bandla, Santhoshi, Jeffrey H. Peters, David Ruff, et al.. (2014). Comparison of Cancer-Associated Genetic Abnormalities in Columnar-Lined Esophagus Tissues With and Without Goblet Cells. Annals of Surgery. 260(1). 72–80. 27 indexed citations

12.

Beauchamp, Ellen M., Brittany A. Woods, Austin Dulak, et al.. (2013). Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss. Molecular Cancer Therapeutics. 13(2). 475–482. 44 indexed citations

13.

Habibollahi, Peiman, Jose‐Luiz Figueiredo, Pedram Heidari, et al.. (2012). Optical Imaging with a Cathepsin B Activated Probe for the Enhanced Detection of Esophageal Adenocarcinoma by Dual Channel Fluorescent Upper GI Endoscopy. Theranostics. 2(2). 227–234. 40 indexed citations

14.

Dulak, Austin, et al.. (2011). HGF-independent potentiation of EGFR action by c-Met. Oncogene. 30(33). 3625–3635. 94 indexed citations

15.

Wang, Peng, Fangdong Zou, Xiaodong Zhang, et al.. (2009). microRNA-21 Negatively Regulates Cdc25A and Cell Cycle Progression in Colon Cancer Cells. Cancer Research. 69(20). 8157–8165. 261 indexed citations

16.

Stabile, Laura P., Mary E. Rothstein, Phouthone Keohavong, et al.. (2008). Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Molecular Cancer Therapeutics. 7(7). 1913–1922. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact